Actor David Krumholtz’s experience with Cannabinoid Hyperemesis Syndrome sparked a backlash that reveals a deeper problem in cannabis culture. This piece examines how rare conditions get weaponized, why defensive reactions backfire, and how patients, veterans, and families are erased when nuance collapses on both sides of the cannabis debate.
Reefer Report Card Vol. 32: Kicking the Can Again
This week’s Reefer Report Card tracks a familiar pattern in cannabis policy: delay dressed as progress. Federal lawmakers punted again on hemp regulation, states flirted with dismantling legal markets, and patients were left waiting. Oversight weakened, accountability faded, and reform stalled. Another week in weed, graded.
WHEN THE UN CAN’T STOP LEGAL WEED
As cannabis reform accelerates worldwide, the UN’s International Narcotics Control Board continues warning that decades old drug treaties still apply. This feature examines the INCB’s actual authority, the limits of treaty enforcement, and why global legalization is advancing despite institutional resistance rooted in prohibition era frameworks.
The Federal Hemp Blueprint That Isn’t
A proposed federal hemp framework is being sold as long overdue clarity for a chaotic market. But beneath the promise of order, the structure reveals rigid caps, unresolved enforcement questions, and a quiet shift of power away from states and smaller producers. We break down what the proposal does, what it avoids, and why the difference matters.
Reefer Report Card Vol. 31: The Retreat Becomes Routine
Reefer Report Card Vol. 31 examines a week where cannabis reform quietly retreated. Ballot rollbacks gained traction, federal action stalled, and patients remained unprotected. Legal weed stayed popular, but oversight weakened and accountability slipped. Another week where legalization survived while governance failed
Reefer Report Card Vol. 30: The Floor Starts to Give
Reefer Report Card Vol. 30 tracks a week where legalization stalled while rollback efforts gained ground. Ballot initiatives threatened regulated markets, federal reform stayed stalled, and patients were left navigating uncertainty. Demand remained strong, but oversight weakened. Another week where cannabis survived while governance quietly failed.